JSON
Huang H, Angeletti D
Trends Immunol 44 (11) 874-876
[2023-11-00; online 2023-10-05]
SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.
PubMed 37805348
DOI 10.1016/j.it.2023.09.006
Crossref 10.1016/j.it.2023.09.006
pii: S1471-4906(23)00202-8